In vitro antimicrobial activity of T-2588 (T-2525) and its therapeutic efficacy on lower respiratory infections

Akira Watanabe, Akio Ebina, Kotaro Oizumi, Masako Sasaki, Seuchi Aonuma, Kikuo Onuma, Reiko Ono, Yoshihiro Honda, Noriko Otani, Kiyoshi Konno, Kiyoshi Kawamorita, Tsugushi Ito

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)


    T-2588, an ester derivative of T-2525, was developed in Japan as a new cephem for oral use. In vitro antimicrobial activity of T-2525 was examined by a broth dilution method using the Dynatech MIC 2000 system, and therapeutic effects of T-2588 on lower respiratory infections were evaluated. The minimum inhibitory concentrations(MlCs) of T-2525, cefixime(CFIX), cefaclor(CCL), cephalexin(CEX) and amoxicillin(AMPC) against 223 clinical isolates consisting of nine species were determined. T-2525 was more highly active against H. influenzae and E.coli than any other antibiotics. T-2525 was almost as active as cephalexin or cefaclor against S. aureus, and as active as amoxicillin against S. pneumoniae and S. pyogenes. T-2525 was as active as cefixime against E. cloacae. Against K. pneumoniae and S. marcescens, T-2525 was more active than cefaclor or amoxicillin, but somewhat less active than cefixime. T-2525 was found to be less active against all the strains tested of P. aeruginosa with MlCs above 100 μg/ml. A daily dose of 200 to 600 milligrams of T-2588 was given orally to a total of 16 cases which consisted of one patient with acute bronchitis, eight patients with acute pneumonia, six patients with chronic respiratory diseases and one patient with infection associated with lung cancer. The clinical effects were excellent in four patients, good in 11, and there was no case evaluated as fair or poor. One patient with Mycoplasma pneumoniae pneumonia was excluded from clinical evaluation. A total of eleven strains which consisted of two strains of S. pneumoniae, eight strains of H. in fluenzae and one strain of K. pneumoniae, were identified as causative organisms, and all of them were eradicated by the treatment with T-2588. No any side effect was observed in all patients. An elevation of values of serum transaminase was observed in two patients. These adverse reactions disappeared after completion of the therapy with T-2588. From the above results, it was concluded that T-2588 is one of the most useful antibiotics for oral use, for the treatment of lower respiratory infections.

    Original languageEnglish
    Pages (from-to)281-294
    Number of pages14
    Publication statusPublished - 1986 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'In vitro antimicrobial activity of T-2588 (T-2525) and its therapeutic efficacy on lower respiratory infections'. Together they form a unique fingerprint.

    Cite this